

Manish K Aghi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3807812/publications.pdf>

Version: 2024-02-01

230
papers

16,331
citations

25014

57
h-index

18115

120
g-index

238
all docs

238
docs citations

238
times ranked

27479
citing authors

#	ARTICLE	IF	CITATIONS
1	Trends in physician reimbursements and procedural volumes for radiosurgery versus open surgery in brain tumor care: an analysis of Medicare data from 2009 to 2018. <i>Journal of Neurosurgery</i> , 2022, 136, 97-108.	0.9	1
2	The Evolving Role of Neurosurgical Intervention for Central Nervous System Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 63-75.	0.9	1
3	Socioeconomic predictors of case presentations and outcomes in 225 nonfunctional pituitary adenoma resections. <i>Journal of Neurosurgery</i> , 2022, 136, 1325-1336.	0.9	4
4	CD97 is associated with mitogenic pathway activation, metabolic reprogramming, and immune microenvironment changes in glioblastoma. <i>Scientific Reports</i> , 2022, 12, 1464.	1.6	8
5	Effect of facility volume on giant pituitary adenoma neurosurgical outcomes. <i>Journal of Neurosurgery</i> , 2022, , 1-10.	0.9	2
6	The immunology of low-grade gliomas. <i>Neurosurgical Focus</i> , 2022, 52, E2.	1.0	20
7	Identifying risk factors for postoperative diabetes insipidus in more than 2500 patients undergoing transsphenoidal surgery: a single-institution experience. <i>Journal of Neurosurgery</i> , 2022, 137, 647-657.	0.9	11
8	Sarcopenia Diagnosed Using Masseter Muscle Diameter as a Survival Correlate in Elderly Patients with Glioblastoma. <i>World Neurosurgery</i> , 2022, 161, e448-e463.	0.7	5
9	Surgery for Control of Brain Metastases After Previous Checkpoint Inhibitor Immunotherapy. <i>World Neurosurgery</i> , 2022, 162, e235-e245.	0.7	2
10	Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions. <i>Seminars in Cancer Biology</i> , 2022, 86, 532-541.	4.3	14
11	Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes. <i>Neuro-Oncology</i> , 2022, 24, 1749-1762.	0.6	10
12	Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type Glioblastoma. <i>Neurosurgery</i> , 2022, 90, 124-130.	0.6	17
13	Recent advancements in the molecular biology of pituitary adenomas. <i>Expert Review of Endocrinology and Metabolism</i> , 2022, 17, 293-304.	1.2	3
14	Anti-angiogenic therapies in the management of glioblastoma. <i>Chinese Clinical Oncology</i> , 2021, 10, 37-37.	0.4	11
15	Comparative Analysis of Survival Outcomes and Prognostic Factors of Supratentorial versus Cerebellar Glioblastoma in the Elderly: Does Location Really Matter?. <i>World Neurosurgery</i> , 2021, 146, e755-e767.	0.7	7
16	Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies. <i>Journal of Neuro-Oncology</i> , 2021, 152, 1-13.	1.4	7
17	Introduction to special issue dedicated to the 35th anniversary of the joint section on tumors. <i>Journal of Neuro-Oncology</i> , 2021, 151, 341-343.	1.4	1
18	Beyond guidelines: analysis of current practice patterns of AANS/CNS tumor neurosurgeons. <i>Journal of Neuro-Oncology</i> , 2021, 151, 361-366.	1.4	2

#	ARTICLE	IF	CITATIONS
19	Can Private versus Government Insurance Predict Neurosurgical Outcomes? An Analysis of 218 Nonfunctional Pituitary Adenoma Resections across Seven Years. , 2021, 82, .		0
20	Does Having a Primary Care Physician Predict Neurosurgical Outcomes? An Analysis of 225 Nonfunctional Pituitary Adenoma Resections across Seven Years. , 2021, 82, .		0
21	Convection-enhanced drug delivery for glioblastoma: a review. <i>Journal of Neuro-Oncology</i> , 2021, 151, 415-427.	1.4	50
22	Hyperostosing sphenoid wing meningiomas: surgical outcomes and strategy for bone resection and multidisciplinary orbital reconstruction. <i>Journal of Neurosurgery</i> , 2021, 134, 711-720.	0.9	17
23	The Role of Cancer-Associated Fibroblasts in Tumor Progression. <i>Cancers</i> , 2021, 13, 1399.	1.7	98
24	Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 3916-3925.	3.2	24
25	A Safe Transitions Pathway for post-craniotomy neurological surgery patients: high-value care that bypasses the intensive care unit. <i>Journal of Neurosurgery</i> , 2021, 134, 1386-1391.	0.9	9
26	Meningioma surgical outcomes and complications in patients aged 75 years and older. <i>Journal of Clinical Neuroscience</i> , 2021, 88, 88-94.	0.8	2
27	Role of c-Met/ α 21 integrin complex in the metastatic cascade in breast cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	12
28	Detection of glioma infiltration at the tumor margin using quantitative stimulated Raman scattering histology. <i>Scientific Reports</i> , 2021, 11, 12162.	1.6	28
29	Metabolic Drivers of Invasion in Glioblastoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 683276.	1.8	31
30	OTME-12. Role of the transsulfuration pathway in glioblastoma invasion. <i>Neuro-Oncology Advances</i> , 2021, 3, ii15-ii16.	0.4	0
31	Plurihormonal PIT-1 Positive Pituitary Adenomas: A Systematic Review and Single-Center Series. <i>World Neurosurgery</i> , 2021, 151, e185-e191.	0.7	4
32	Presentation and management of post-operative cerebrospinal fluid leaks after sphenoclivar expanded endonasal surgery: A single institution experience. <i>Journal of Clinical Neuroscience</i> , 2021, 91, 13-19.	0.8	0
33	Geographic landscape of foreign medical graduates in US neurosurgery training programs from 2007 to 2017. <i>Clinical Neurology and Neurosurgery</i> , 2021, 209, 106891.	0.6	4
34	Mouse models of glioblastoma for the evaluation of novel therapeutic strategies. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab100.	0.4	47
35	Salvage surgery for local control of brain metastases after prior stereotactic radiosurgery: a single-center series. <i>World Neurosurgery</i> , 2021, , .	0.7	0
36	ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma. <i>Genome Biology</i> , 2021, 22, 311.	3.8	25

#	ARTICLE	IF	CITATIONS
37	Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 812916.	1.3	13
38	Immunotherapy Resistance in Glioblastoma. <i>Frontiers in Genetics</i> , 2021, 12, 750675.	1.1	13
39	Autophagy as a mechanism for anti-angiogenic therapy resistance. <i>Seminars in Cancer Biology</i> , 2020, 66, 75-88.	4.3	26
40	Letter to the Editor Regarding "Global Diversity and Academic Success of Foreign-Trained Academic Neurosurgeons in the United States". <i>World Neurosurgery</i> , 2020, 139, 704-705.	0.7	0
41	Letter to the Editor Regarding "Geographic Distribution of International Medical Graduate Residents in U.S. Neurosurgery Training Programs". <i>World Neurosurgery</i> , 2020, 138, 591.	0.7	4
42	Higher cytolytic score correlates with an immunosuppressive tumor microenvironment and reduced survival in glioblastoma. <i>Scientific Reports</i> , 2020, 10, 17580.	1.6	19
43	Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma. <i>Nature Communications</i> , 2020, 11, 4803.	5.8	56
44	WHO Grade I Meningioma Recurrence: Identifying High Risk Patients Using Histopathological Features and the MIB-1 Index. <i>Frontiers in Oncology</i> , 2020, 10, 1522.	1.3	33
45	Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor. <i>Acta Neuropathologica Communications</i> , 2020, 8, 151.	2.4	35
46	Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa142.	0.4	35
47	Incorporating Tumor-Associated Macrophages into Engineered Models of Glioma. <i>iScience</i> , 2020, 23, 101770.	1.9	18
48	In Reply to the Letter to the Editor "Regarding the Path to U.S. Neurosurgical Residency for Foreign Medical Graduates: Trends from a Decade 2007-2017". <i>World Neurosurgery</i> , 2020, 143, 625.	0.7	0
49	Strategies to Address Projected Challenges Facing Foreign Applicants in the U.S. Neurosurgery Match. <i>World Neurosurgery</i> , 2020, 138, 553-555.	0.7	5
50	In Reply to the Letter to the Editor Regarding "The Path to U.S. Neurosurgical Residency for Foreign Medical Graduates: Trends from a Decade 2007-2017". <i>World Neurosurgery</i> , 2020, 138, 594.	0.7	0
51	Atypical meningiomas. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2020, 170, 233-244.	1.0	10
52	Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. <i>Neuro-Oncology</i> , 2020, 22, 1568-1579.	0.6	38
53	The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment. <i>Journal of Neuro-Oncology</i> , 2020, 148, 131-139.	1.4	15
54	The Path to U.S. Neurosurgical Residency for Foreign Medical Graduates: Trends from a Decade 2007-2017. <i>World Neurosurgery</i> , 2020, 137, e584-e596.	0.7	42

#	ARTICLE	IF	CITATIONS
55	Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 495.	3.4	325
56	Endoscopic skull base and transoral surgery during COVID-19 pandemic: Minimizing droplet spread with negative-pressure otolaryngology viral isolation drape. <i>Head and Neck</i> , 2020, 42, 1577-1582.	0.9	47
57	Inpatient and outpatient case prioritization for patients with neuro-oncologic disease amid the COVID-19 pandemic: general guidance for neuro-oncology practitioners from the AANS/CNS Tumor Section and Society for Neuro-Oncology. <i>Journal of Neuro-Oncology</i> , 2020, 147, 525-529.	1.4	76
58	Shunt Treatment for Coccidioidomycosis-Related Hydrocephalus: A Single-Center Series. <i>World Neurosurgery</i> , 2020, 138, e883-e891.	0.7	6
59	Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance. <i>Cancer Research</i> , 2020, 80, 1498-1511.	0.4	35
60	Meningioma metastases: incidence and proposed screening paradigm. <i>Journal of Neurosurgery</i> , 2020, 132, 1447-1455.	0.9	41
61	Clinical characteristics and outcomes of null-cell versus silent gonadotroph adenomas in a series of 1166 pituitary adenomas from a single institution. <i>Neurosurgical Focus</i> , 2020, 48, E13.	1.0	22
62	Cerebrospinal Fluid Leaks and Pseudomeningocele after Posterior Fossa Surgery: Effect of an Autospray Dural Sealant. <i>Cureus</i> , 2020, 12, e8379.	0.2	4
63	Interfacility neurosurgical transfers: an analysis of nontraumatic inpatient and emergency department transfers with implications for improvements in care. <i>Journal of Neurosurgery</i> , 2019, 131, 281-289.	0.9	13
64	Surgical Outcomes, Complications, and Management Strategies for Foramen Magnum Meningiomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2019, 80, 001-009.	0.4	16
65	Functional brain mapping: overview of techniques and their application to neurosurgery. <i>Neurosurgical Review</i> , 2019, 42, 639-647.	1.2	21
66	Dissecting and rebuilding the glioblastoma microenvironment with engineered materials. <i>Nature Reviews Materials</i> , 2019, 4, 651-668.	23.3	103
67	Systemic therapy for brain metastases. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 44-50.	2.0	41
68	Fibronectin in malignancy: Cancer-specific alterations, protumoral effects, and therapeutic implications. <i>Seminars in Oncology</i> , 2019, 46, 284-290.	0.8	68
69	Molecular Biology of Pituitary Adenomas. <i>Neurosurgery Clinics of North America</i> , 2019, 30, 391-400.	0.8	13
70	Introduction to Pituitary Adenomas. <i>Neurosurgery Clinics of North America</i> , 2019, 30, xiii.	0.8	1
71	The Phenotypes of Proliferating Glioblastoma Cells Reside on a Single Axis of Variation. <i>Cancer Discovery</i> , 2019, 9, 1708-1719.	7.7	205
72	Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β 1 Blocking Antibody OS2966. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1127-1136.	1.9	22

#	ARTICLE	IF	CITATIONS
73	Immunotherapy for High-Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons. <i>World Neurosurgery</i> , 2019, 124, 397-409.	0.7	19
74	Endoscope Image Capture System with Mirrorless Camera. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2019, 80, 079-081.	0.4	0
75	The Role of Single-Nucleotide Polymorphisms in Pituitary Adenomas Tumorigenesis. <i>Cancers</i> , 2019, 11, 1977.	1.7	3
76	Growth hormone and prolactin-staining tumors causing acromegaly: a retrospective review of clinical presentations and surgical outcomes. <i>Journal of Neurosurgery</i> , 2019, 131, 147-153.	0.9	19
77	The genetic landscape of gliomas arising after therapeutic radiation. <i>Acta Neuropathologica</i> , 2019, 137, 139-150.	3.9	57
78	Presence of Histopathological Treatment Effects at Resection of Recurrent Glioblastoma: Incidence and Effect on Outcome. <i>Neurosurgery</i> , 2019, 85, 793-800.	0.6	10
79	Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes. <i>Oncotarget</i> , 2019, 10, 2212-2223.	0.8	33
80	Economic Burden and Cost-effectiveness of Endoscopic versus Microscopic Transsphenoidal Surgery for Pituitary Adenomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2019, 80, .	0.4	0
81	Correction: Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes. <i>Oncotarget</i> , 2019, 10, 4350-4350.	0.8	1
82	Postoperative Delirium in Glioblastoma Patients: Risk Factors and Prognostic Implications. <i>Neurosurgery</i> , 2018, 83, 1161-1172.	0.6	29
83	Salvage therapy outcomes for atypical meningioma. <i>Journal of Neuro-Oncology</i> , 2018, 138, 425-433.	1.4	25
84	A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment. <i>Cancer Cell</i> , 2018, 33, 874-889.e7.	7.7	180
85	Tuberculum sellae meningiomas: grading scale to assess surgical outcomes using the transcranial versus transsphenoidal approach. <i>Neurosurgical Focus</i> , 2018, 44, E9.	1.0	81
86	Petrous Face Meningiomas: Classification, Clinical Syndromes, and Surgical Outcomes. <i>World Neurosurgery</i> , 2018, 114, e1266-e1274.	0.7	17
87	Tumor treating fields: a new approach to glioblastoma therapy. <i>Journal of Neuro-Oncology</i> , 2018, 137, 447-453.	1.4	38
88	A cross-sectional study of neurosurgical department chairs in the United States. <i>Journal of Neurosurgery</i> , 2018, 129, 1342-1348.	0.9	16
89	Initial Experience with Intraoperative Phosphorous-32 Brachytherapy During Resection of Malignant Spinal Tumors. <i>World Neurosurgery</i> , 2018, 115, e785-e793.	0.7	0
90	Atypical pituitary adenoma: a clinicopathologic case series. <i>Journal of Neurosurgery</i> , 2018, 128, 1058-1065.	0.9	20

#	ARTICLE	IF	CITATIONS
91	Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. <i>Neuro-Oncology</i> , 2018, 20, 632-641.	0.6	33
92	The Endoscopic Buccal Fat Pad Flap for Closure of Skull Base Defects: A Report of 5 Cases. <i>World Neurosurgery</i> , 2018, 110, e42-e45.	0.7	2
93	Disparities in health care determine prognosis in newly diagnosed glioblastoma. <i>Neurosurgical Focus</i> , 2018, 44, E16.	1.0	35
94	Safety and outcomes of resection of butterfly glioblastoma. <i>Neurosurgical Focus</i> , 2018, 44, E4.	1.0	43
95	Histopathological features predictive of local control of atypical meningioma after surgery and adjuvant radiotherapy. <i>Journal of Neurosurgery</i> , 2018, 130, 1-8.	0.9	54
96	Medical versus surgical treatment of prolactinomas: an analysis of treatment outcomes. <i>Expert Review of Endocrinology and Metabolism</i> , 2018, 13, 25-33.	1.2	8
97	Developing an Algorithm for Optimizing Care of Elderly Patients With Glioblastoma. <i>Neurosurgery</i> , 2018, 82, 64-75.	0.6	22
98	Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. <i>Journal of Neurosurgery</i> , 2017, 126, 191-200.	0.9	148
99	Ventriculoperitoneal Shunting for Glioblastoma: Risk Factors, Indications, and Efficacy. <i>Neurosurgery</i> , 2017, 80, 421-430.	0.6	27
100	Role of a p53 polymorphism in the development of nonfunctional pituitary adenomas. <i>Molecular and Cellular Endocrinology</i> , 2017, 446, 81-90.	1.6	16
101	Improved Survival with Decreased Wait Time to Surgery in Glioblastoma Patients Presenting with Seizure. <i>Neurosurgery</i> , 2017, 81, 824-833.	0.6	30
102	Cross-activating c-Met/ β 1 integrin complex drives metastasis and invasive resistance in cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E8685-E8694.	3.3	60
103	Indications and Efficacy of Gamma Knife Stereotactic Radiosurgery for Recurrent Glioblastoma: 2 Decades of Institutional Experience. <i>Neurosurgery</i> , 2017, 80, 129-139.	0.6	33
104	Patients cured of acromegaly do not experience improvement of their skull deformities. <i>Pituitary</i> , 2017, 20, 292-294.	1.6	7
105	Cost-Effectiveness Analysis of Surgical versus Medical Treatment of Prolactinomas. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2017, 78, 125-131.	0.4	24
106	Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. <i>Genome Biology</i> , 2017, 18, 234.	3.8	448
107	Management of Chordoma and Chondrosarcoma with Fractionated Stereotactic Radiotherapy. <i>Frontiers in Surgery</i> , 2017, 4, 35.	0.6	20
108	Neuropilin-1 modulates TGF β 2 signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy. <i>PLoS ONE</i> , 2017, 12, e0185065.	1.1	35

#	ARTICLE	IF	CITATIONS
109	GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance. JCI Insight, 2017, 2, e88815.	2.3	49
110	Pituitary Apoplexy. , 2017, , 499-516.		0
111	Atypical Pituitary Adenoma: A Clinicopathologic Case Series. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, S1-S156.	0.4	0
112	Neuroendocrinological Outcomes Following Early versus Delayed Surgery for Acute Pituitary Apoplexy. Journal of Neurological Surgery, Part B: Skull Base, 2017, 78, S1-S156.	0.4	0
113	ACTR-33. AÂPHASE IÂSTUDY OF CONVECTION-ENHANCED DELIVERY OF LIPOSOMAL-IRINOTECAN USING REAL-TIME IMAGING WITH GADOLINIUM IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA. Neuro-Oncology, 2016, 18, vi9-vi9.	0.6	0
114	TMOD-24. AÂNOVEL XENOGRAFT MODEL REVEALS AÂGENE CASCADE DEFINING AÂMESENCHYMAL TRANSITION DURING THE EVOLUTION OF RESISTANCE TO ANTI-ANGIOGENIC THERAPY. Neuro-Oncology, 2016, 18, vi212-vi212.	0.6	0
115	Singleâ€cell sequencing maps gene expression to mutational phylogenies in <scp>PDGF</scp> â€and <scp>EGF</scp> â€driven gliomas. Molecular Systems Biology, 2016, 12, 889.	3.2	91
116	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for the Management of Patients With Residual or Recurrent Nonfunctioning Pituitary Adenomas. Neurosurgery, 2016, 79, E539-E540.	0.6	59
117	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Management of Patients With Nonfunctioning Pituitary Adenomas. Neurosurgery, 2016, 79, 521-523.	0.6	38
118	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for Pretreatment Endocrine Evaluation of Patients With Nonfunctioning Pituitary Adenomas. Neurosurgery, 2016, 79, E527-E529.	0.6	40
119	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Primary Management of Patients With Nonfunctioning Pituitary Adenomas. Neurosurgery, 2016, 79, E533-E535.	0.6	77
120	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Surgical Techniques and Technologies for the Management of Patients With Nonfunctioning Pituitary Adenomas. Neurosurgery, 2016, 79, E536-E538.	0.6	44
121	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Posttreatment Follow-up Evaluation of Patients With Nonfunctioning Pituitary Adenomas. Neurosurgery, 2016, 79, E541-E543.	0.6	34
122	Interventional MRI-guided catheter placement and real time drug delivery to the central nervous system. Expert Review of Neurotherapeutics, 2016, 16, 635-639.	1.4	21
123	Resection and brain brachytherapy with permanent iodine-125 sources for brain metastasis. Journal of Neurosurgery, 2016, 126, 1749-1755.	0.9	33
124	The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma. Academic Radiology, 2016, 23, 1073-1082.	1.3	14
125	Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. Journal of Neuro-Oncology, 2016, 130, 543-552.	1.4	90
126	Surgical resection of fourth ventricular ependymomas: case series and technical nuances. Journal of Neuro-Oncology, 2016, 130, 341-349.	1.4	20

#	ARTICLE	IF	CITATIONS
127	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Pretreatment Ophthalmology Evaluation in Patients With Suspected Nonfunctioning Pituitary Adenomas. Neurosurgery, 2016, 79, E530-E532.	0.6	32
128	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Preoperative Imaging Assessment of Patients With Suspected Nonfunctioning Pituitary Adenomas. Neurosurgery, 2016, 79, E524-E526.	0.6	20
129	Preventing Delays in First-Case Starts on the Neurosurgery Service: A Resident-Led Initiative at an Academic Institution. Journal of Surgical Education, 2016, 73, 291-295.	1.2	18
130	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
131	Nationwide shift from microscopic to endoscopic transsphenoidal pituitary surgery. Pituitary, 2016, 19, 248-250.	1.6	68
132	Improved versus worsened endocrine function after transsphenoidal surgery for nonfunctional pituitary adenomas: rate, time course, and radiological analysis. Journal of Neurosurgery, 2016, 124, 589-595.	0.9	75
133	Surgical Cavity Constriction and Local Progression Between Resection and Adjuvant Radiosurgery for Brain Metastases. Cureus, 2016, 8, e575.	0.2	21
134	Antiangiogenic Therapy for Glioblastoma. , 2016, , 143-149.		1
135	BMET-24CRANIOTOMY FOR TUMOR RESECTION IN PATIENTS WITH MULTIPLE BRAIN METASTASES: CHARACTERISTIC OF THE DOMINANT METASTATIC LESION. Neuro-Oncology, 2015, 17, v50.2-v50.	0.6	0
136	Sinonasal morbidity following endoscopic endonasal skull base surgery. Clinical Neurology and Neurosurgery, 2015, 130, 162-167.	0.6	71
137	Adaptation to antiangiogenic therapy in neurological tumors. Cellular and Molecular Life Sciences, 2015, 72, 3069-3082.	2.4	4
138	Incidence of headache as a presenting complaint in over 1000 patients with sellar lesions and factors predicting postoperative improvement. Clinical Neurology and Neurosurgery, 2015, 132, 16-20.	0.6	27
139	Factors Predicting Recurrence After Resection of Clival Chordoma Using Variable Surgical Approaches and Radiation Modalities. Neurosurgery, 2015, 76, 179-186.	0.6	72
140	Risk factors for postoperative cerebrospinal fluid leak and meningitis after expanded endoscopic endonasal surgery. Journal of Clinical Neuroscience, 2015, 22, 48-54.	0.8	129
141	A predictive algorithm for evaluating elevated serum prolactin in patients with a sellar mass. Journal of Clinical Neuroscience, 2015, 22, 155-160.	0.8	8
142	Hypophysitis: a single-center case series. Pituitary, 2015, 18, 630-641.	1.6	60
143	HIGD1A Regulates Oxygen Consumption, ROS Production, and AMPK Activity during Glucose Deprivation to Modulate Cell Survival and Tumor Growth. Cell Reports, 2015, 10, 891-899.	2.9	79
144	Approach to the postoperative patient with Cushing's disease. Pituitary, 2015, 18, 232-237.	1.6	8

#	ARTICLE	IF	CITATIONS
145	Epidermal growth factor-like module containing mucin-like hormone receptor 2 expression in gliomas. <i>Journal of Neuro-Oncology</i> , 2015, 121, 53-61.	1.4	7
146	Convection-enhanced delivery for the treatment of glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, ii3-ii8.	0.6	124
147	The role of surgery in the management of patients with diffuse low grade glioma. <i>Journal of Neuro-Oncology</i> , 2015, 125, 503-530.	1.4	147
148	Microarray Analysis in Glioblastomas. <i>Methods in Molecular Biology</i> , 2015, 1375, 195-206.	0.4	6
149	Pituicytomas and spindle cell oncocytomas: modern case series from the University of California, San Francisco. <i>Pituitary</i> , 2015, 18, 150-158.	1.6	60
150	Intraoperative Conversion from Endoscopic to Open Transcortical Transventricular Removal of Colloid Cysts as a Salvage Procedure. <i>Cureus</i> , 2015, 7, e247.	0.2	4
151	Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids. <i>Molecular Therapy - Methods and Clinical Development</i> , 2014, 1, 14024.	1.8	0
152	Optimizing glioblastoma resection: intraoperative mapping and beyond. <i>CNS Oncology</i> , 2014, 3, 359-366.	1.2	12
153	Getting More Out of Radiation Therapy in Glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 4-6.	0.6	4
154	Tumors of the anterior skull base. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 425-438.	1.4	10
155	Morbidity of repeat transsphenoidal surgery assessed in more than 1000 operations. <i>Journal of Neurosurgery</i> , 2014, 121, 67-74.	0.9	56
156	Gangliogliomas of the optic pathway. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 2244-2249.	0.8	15
157	Extended endoscopic endonasal approach for suprasellar Rathke's cleft cysts. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 779-785.	0.8	15
158	Rathke's cleft cysts: review of natural history and surgical outcomes. <i>Journal of Neuro-Oncology</i> , 2014, 117, 197-203.	1.4	104
159	Heat-shock protein peptide complex ⁹⁶ vaccination for recurrent glioblastoma: a phase II, single-arm trial. <i>Neuro-Oncology</i> , 2014, 16, 274-279.	0.6	188
160	Impact of platybasia and anatomic variance on surgical approaches to the craniovertebral junction. <i>Laryngoscope</i> , 2014, 124, 1760-1766.	1.1	9
161	Cavernous and inferior petrosal sinus sampling and dynamic magnetic resonance imaging in the preoperative evaluation of Cushing's disease. <i>Journal of Neuro-Oncology</i> , 2014, 116, 593-600.	1.4	31
162	β21 Integrin: Critical Path to Antiangiogenic Therapy Resistance and Beyond. <i>Cancer Research</i> , 2014, 74, 3-7.	0.4	84

#	ARTICLE	IF	CITATIONS
163	Outcomes and patterns of care in adult skull base chondrosarcomas from the SEER database. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1497-1502.	0.8	21
164	Use of thrombin-based hemostatic matrix during meningioma resection: A potential risk factor for perioperative thromboembolic events. <i>Clinical Neurology and Neurosurgery</i> , 2014, 119, 116-120.	0.6	22
165	Outcomes and patterns of care in adult skull base chordomas from the Surveillance, Epidemiology, and End Results (SEER) database. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1490-1496.	0.8	76
166	Rate and Time Course of Improvement in Endocrine Function After More Than 1000 Pituitary Operations. <i>Neurosurgery</i> , 2014, 61, 163-166.	0.6	20
167	Surgical outcomes in choroid plexus papillomas: an institutional experience. <i>Journal of Neuro-Oncology</i> , 2013, 113, 117-125.	1.4	29
168	Endoscopic surgery for tuberculom sellae meningiomas: a systematic review and meta-analysis. <i>Neurosurgical Review</i> , 2013, 36, 349-359.	1.2	68
169	Factors predicting postoperative hyponatremia and efficacy of hyponatremia management strategies after more than 1000 pituitary operations. <i>Journal of Neurosurgery</i> , 2013, 119, 1478-1483.	0.9	75
170	Disseminated progression of glioblastoma after treatment with bevacizumab. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1795-1801.	0.6	19
171	The prognostic implications of Hyamâ€™s subtype for patients with Kadish stage C esthesioneuroblastoma. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 281-286.	0.8	51
172	Socioeconomic factors associated with pituitary apoplexy. <i>Journal of Neurosurgery</i> , 2013, 119, 1432-1436.	0.9	21
173	Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance. <i>Clinical Cancer Research</i> , 2013, 19, 1773-1783.	3.2	177
174	Î²1 Integrin Targeting Potentiates Antiangiogenic Therapy and Inhibits the Growth of Bevacizumab-Resistant Glioblastoma. <i>Cancer Research</i> , 2013, 73, 3145-3154.	0.4	140
175	Headache and Focal Neurologic Deficits in a 37-Year-Old Woman. <i>JAMA Neurology</i> , 2013, 70, 1445.	4.5	1
176	A Comprehensive Long-term Retrospective Analysis of Silent Corticotrophic Adenomas vs Hormone-Negative Adenomas. <i>Neurosurgery</i> , 2013, 73, 8-18.	0.6	73
177	Nuclear Localization of the Mitochondrial Factor HIGD1A during Metabolic Stress. <i>PLoS ONE</i> , 2013, 8, e62758.	1.1	32
178	Factors associated with delay to pituitary adenoma diagnosis in patients with visual loss. <i>Journal of Neurosurgery</i> , 2012, 116, 283-289.	0.9	33
179	Regional variation in histopathologic features of tumor specimens from treatment-naïve glioblastoma correlates with anatomic and physiologic MR Imaging. <i>Neuro-Oncology</i> , 2012, 14, 942-954.	0.6	183
180	Microarray Analysis Verifies Two Distinct Phenotypes of Glioblastomas Resistant to Antiangiogenic Therapy. <i>Clinical Cancer Research</i> , 2012, 18, 2930-2942.	3.2	102

#	ARTICLE	IF	CITATIONS
181	Neurosurgical Management and Prognosis of Patients With Glioblastoma That Progresses During Bevacizumab Treatment. <i>Neurosurgery</i> , 2012, 70, 361-370.	0.6	60
182	Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas. <i>Neurosurgery</i> , 2012, 70, 234-244.	0.6	204
183	Preface. <i>Neurosurgery Clinics of North America</i> , 2012, 23, ix.	0.8	0
184	Impact of extent of resection for recurrent glioblastoma on overall survival. <i>Journal of Neurosurgery</i> , 2012, 117, 1032-1038.	0.9	370
185	Tumor Cell Autophagy as an Adaptive Response Mediating Resistance to Treatments Such as Antiangiogenic Therapy. <i>Cancer Research</i> , 2012, 72, 4294-4299.	0.4	170
186	Hypoxia-induced tumor cell autophagy mediates resistance to anti-angiogenic therapy. <i>Autophagy</i> , 2012, 8, 979-981.	4.3	57
187	Hypoxia-Induced Autophagy Promotes Tumor Cell Survival and Adaptation to Antiangiogenic Treatment in Glioblastoma. <i>Cancer Research</i> , 2012, 72, 1773-1783.	0.4	395
188	Intracranial subdural osteoma: A rare benign tumor that can be differentiated from other calcified intracranial lesions utilizing MR imaging. <i>Journal of Neuroradiology</i> , 2012, 39, 263-266.	0.6	11
189	VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex. <i>Cancer Cell</i> , 2012, 22, 21-35.	7.7	495
190	Biomarkers predicting tumor response and evasion to anti-angiogenic therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1825, 86-100.	3.3	17
191	Determinants of initial bone graft volume loss in posterolateral lumbar fusion. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 1193-1196.	0.8	4
192	Suprasellar Rathke Cleft Cysts. <i>Neurosurgery</i> , 2011, 69, 1058-1069.	0.6	65
193	Excess mortality for patients with residual disease following resection of pituitary adenomas. <i>Pituitary</i> , 2011, 14, 276-283.	1.6	46
194	Impact of bevacizumab chemotherapy on craniotomy wound healing. <i>Journal of Neurosurgery</i> , 2011, 114, 1609-1616.	0.9	93
195	A critical evaluation of cystic features in primary glioblastoma as a prognostic factor for survival. <i>Journal of Neurosurgery</i> , 2011, 115, 754-759.	0.9	40
196	Dopamine agonist-resistant prolactinomas. <i>Journal of Neurosurgery</i> , 2011, 114, 1369-1379.	0.9	80
197	Infected Rathke Cleft Cysts. <i>Neurosurgery</i> , 2010, 67, 762-769.	0.6	26
198	MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. <i>Neuro-Oncology</i> , 2010, 12, 822-833.	0.6	74

#	ARTICLE	IF	CITATIONS
199	Interval, acute onset airway obstruction associated with a fracture of the C4 vertebra in a patient with ankylosing spondylitis. <i>Journal of Clinical Neuroscience</i> , 2010, 17, 1085-1088.	0.8	1
200	Mechanisms of evasion to antiangiogenic therapy in glioblastoma. <i>Clinical Neurosurgery</i> , 2010, 57, 123-8.	0.2	18
201	Human Glioblastomaâ€œDerived Cancer Stem Cells: Establishment of Invasive Glioma Models and Treatment with Oncolytic Herpes Simplex Virus Vectors. <i>Cancer Research</i> , 2009, 69, 3472-3481.	0.4	303
202	Phase Ib Trial of Oncolytic Herpes Virus G207 Shows Safety of Multiple Injections and Documents Viral Replication. <i>Molecular Therapy</i> , 2009, 17, 8-9.	3.7	41
203	Bone involvement predicts poor outcome in atypical meningioma. <i>Journal of Neurosurgery</i> , 2009, 111, 464-471.	0.9	73
204	Hypoxia Enhances the Replication of Oncolytic Herpes Simplex Virus. <i>Molecular Therapy</i> , 2009, 17, 51-56.	3.7	64
205	Decreased rate of infection in glioblastoma patients with allelic loss of chromosome 10q. <i>Journal of Neuro-Oncology</i> , 2009, 93, 115-20.	1.4	12
206	Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. <i>Journal of Neuro-Oncology</i> , 2009, 92, 401-415.	1.4	68
207	New advances that enable identification of glioblastoma recurrence. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 648-657.	12.5	134
208	Biology of Angiogenesis and Invasion in Glioma. <i>Neurotherapeutics</i> , 2009, 6, 447-457.	2.1	174
209	LONG-TERM RECURRENCE RATES OF ATYPICAL MENINGIOMAS AFTER GROSS TOTAL RESECTION WITH OR WITHOUT POSTOPERATIVE ADJUVANT RADIATION. <i>Neurosurgery</i> , 2009, 64, 56-60.	0.6	418
210	Recent advances in the treatment of acromegaly. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2009, 16, 304-307.	1.2	6
211	Management of recurrent and refractory Cushing disease. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 560-568.	2.9	40
212	Management of recurrent and refractory Cushing's disease with reoperation and/or proton beam radiosurgery. <i>Clinical Neurosurgery</i> , 2008, 55, 141-4.	0.2	30
213	Angiogenic Response Caused by Oncolytic Herpes Simplex Virusâ€œInduced Reduced Thrombospondin Expression Can Be Prevented by Specific Viral Mutations or by Administering a Thrombospondin-Derived Peptide. <i>Cancer Research</i> , 2007, 67, 440-444.	0.4	62
214	INCREASED PREVALENCE OF OBESITY AND OBESITY-RELATED POSTOPERATIVE COMPLICATIONS IN MALE PATIENTS WITH MENINGIOMAS. <i>Neurosurgery</i> , 2007, 61, 754-761.	0.6	30
215	Increased prevalence of obesity and obesity-related postoperative complications in male meningioma patients. <i>Clinical Neurosurgery</i> , 2007, 54, 236-40.	0.2	4
216	Unilateral vestibular schwannoma with other neurofibromatosis Type 2â€œrelated tumors: clinical and molecular study of a unique phenotype. <i>Journal of Neurosurgery</i> , 2006, 104, 201-207.	0.9	19

#	ARTICLE	IF	CITATIONS
217	Effect of Chemotherapy-Induced DNA Repair on Oncolytic Herpes Simplex Viral Replication. Journal of the National Cancer Institute, 2006, 98, 38-50.	3.0	135
218	Tumor Stromal-Derived Factor-1 Recruits Vascular Progenitors to Mitotic Neovasculature, where Microenvironment Influences Their Differentiated Phenotypes. Cancer Research, 2006, 66, 9054-9064.	0.4	165
219	Gene therapy for glioblastoma. Neurosurgical Focus, 2006, 20, E18.	1.0	13
220	Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair. Clinical Neurosurgery, 2006, 53, 65-76.	0.2	6
221	Heparin-induced Thrombocytopenia Type II in Subarachnoid Hemorrhage Patients: Incidence and Complications. Neurosurgery, 2005, 57, 243-248.	0.6	34
222	Oncolytic viral therapies – the clinical experience. Oncogene, 2005, 24, 7802-7816.	2.6	269
223	Breast Adenocarcinoma Metastatic to Epidural Cervical Spine Meningioma: Case Report and Review of the Literature. Journal of Neuro-Oncology, 2005, 75, 149-155.	1.4	48
224	Contribution of Bone Marrow-Derived Cells to Blood Vessels in Ischemic Tissues and Tumors. Molecular Therapy, 2005, 12, 994-1005.	3.7	74
225	Magnetic Resonance Imaging Characteristics Predict Epidermal Growth Factor Receptor Amplification Status in Glioblastoma. Clinical Cancer Research, 2005, 11, 8600-8605.	3.2	103
226	Viral vectors as therapeutic agents for glioblastoma. Current Opinion in Molecular Therapeutics, 2005, 7, 419-30.	2.8	17
227	Genetically Engineered Herpes Simplex Viral Vectors in the Treatment of Brain Tumors: A Review. Cancer Investigation, 2003, 21, 278-292.	0.6	14
228	Viral Therapy for Glioblastoma. Cancer Journal (Sudbury, Mass), 2003, 9, 167-179.	1.0	36
229	Prodrug activation enzymes in cancer gene therapy. Journal of Gene Medicine, 2000, 2, 148-164.	1.4	191
230	Lateral orientation of Rathke cleft cysts may be associated with high rates of recurrence after surgery. Pituitary, 0, , .	1.6	0